4.6 Article

Molecular crosstalk between CUEDC2 and ERα influences the clinical outcome by regulating mitosis in breast cancer

期刊

CANCER GENE THERAPY
卷 29, 期 11, 页码 1697-1706

出版社

SPRINGERNATURE
DOI: 10.1038/s41417-022-00494-x

关键词

-

资金

  1. Early Career Award, Science & Engineering Research Board (SERB)-Dept. of Science and Technology (DST), Govt of India [ECR/2015/000206]
  2. Department of Science & Technology and Biotechnology (DSTBT), Govt. of West Bengal [FST/P/ST/9G-21/2016]
  3. University Grants Commission-Junior Research Fellowship [771/CSIR-UGC NET-2017]
  4. ICMR Emeritus Scientist fellowship

向作者/读者索取更多资源

This study reveals the role of CUEDC2 in breast cancer, especially in endocrine resistance and mitotic progression. Upregulation of CUEDC2 renders ERα+ve tumors behave similarly to HR-ve tumors with an increase in aneuploidy. Furthermore, CUEDC2 is identified as a potential prognostic marker and therapeutic target in breast cancer management.
Development of endocrine resistance in hormone-receptor-positive (HR+ve) subtype and lack of definitive target in triple-negative subtype challenge breast cancer management. Contributing to such endocrine resistance is a protein called CUEDC2. It degrades hormone receptors, estrogen receptor-alpha (ER alpha) and progesterone receptor. Higher level of CUEDC2 in ER alpha+ve breast cancer corresponded to poorer disease prognosis. It additionally influences mitotic progression. However, the crosstalk of these two CUEDC2-driven functions in the outcome of breast cancer remained elusive. We showed that CUEDC2 degrades ER alpha during mitosis, utilising the mitotic-ubiquitination-machinery. We elucidated the importance of mitosis-specific phosphorylation of CUEDC2 in this process. Furthermore, upregulated CUEDC2 overrode mitotic arrest, increasing aneuploidy. Finally, recruiting a prospective cohort of breast cancer, we found significantly upregulated CUEDC2 in HR-ve cases. Moreover, individuals with higher CUEDC2 levels showed a poorer progression-free-survival. Together, our data confirmed that CUEDC2 up-regulation renders ER alpha+ve malignancies to behave essentially as HR-ve tumors with the prevalence of aneuploidy. This study finds CUEDC2 as a potential prognostic marker and a therapeutic target in the clinical management of breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据